INTRODUCTION
Bone marrow fibrosis may be present at chronic myeloid leukemia (CML) diagnosis and has been historically associated with poorer treatment responses. Its prognostic value is unclear for clinical outcomes in the current tyrosine kinase inhibitor (TKI) era.
METHODS
We conducted a single-center retrospectiv...
Arjen Yousefi, M. Levin, P. Westerweel· Acta Haematologica· 0 citations
Abstract Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations. Here, we used data from a randomized phase II clin...
J. Hermansen, Weikaixin Kong, Andrea M. Brodersen et al.· HemaSphere· 0 citations
BACKGROUND
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population-level outcomes remain...
M. Brink, Arie C. van der Spek, J. Doorduijn et al.· European Journal of Haematol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.